Linked Life Data

21696048

Source:http://linkedlifedata.com/resource/pubmed/id/21696048

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-6-23
pubmed:abstractText
Our understanding of the role of DSA in both early and late renal allograft injury has advanced significantly over the past decade. Novel protocols have been developed that have led to improved outcomes both in overcoming a positive crossmatch and in the treatment of early AMR. Early experience with bortezomib and eculizumab are encouraging and suggest the possibility of validation in controlled clinical trials. While alloantibody remains an extremely difficult clinical problem and it is unclear if overcoming early hurdles will only be followed by another major hurdle of chronic antibody mediated injury. However, it is clear that significant advances have occurred and if future studies can be designed appropriately, then our ability to control alloantibody in sensitized patients will continue to improve.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0890-9016
pubmed:author
pubmed:issnType
Print
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
307-15
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Clinical management of renal transplant patients with donor-specific alloantibody: the state of the art.
pubmed:affiliation
Von Liebig Transplant Center, Department of Surgery, Division of Transplant Surgery Mayo Clinic, Rochester, MN, USA.
pubmed:publicationType
Journal Article, Review